Podcasts about Incyte

FDA's new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses how FDA's new, interim leaders have changed the tone at the agency and why they are putting medicines derailed under former FDA Commissioner Marty Makary back on track. Usdin also highlights FDA's new real-time clinical trials initiative.BioCentury's analysts then turn to deals, including an analysis of the 20 deals Eli Lilly has done this year; Servier's move to expand in neurology via BD; and Monday's billion-dollar deals by Incyte, which will acquire Vega Therapeutics, and Johnson & Johnson, which is buying Firefly Bio.The team also discusses Grand Rounds U.S., held last week in Seattle, including the conference's Rising Star prize winner Sylvain Simon of Fred Hutchinson Cancer Center.View full story: https://www.biocentury.com/article/659699#FDA #BiopharmaDeals #ClinicalTrials #BiotechMA #GrandRoundsUS01:23 - Grand Rounds Seattle Takeaways04:43 - FDA's New Leaders11:48 - FDA's Real Time Trials Pilot20:40 - Servier Bets on Neuro25:33 - Lilly's Deal Spree30:21 - Dealmaking RoundupTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode, we talk with Christy Donovan, DNP, RN, a Blood Cancer Coordinator at the the Blood and Marrow Transplant/ Leukemia Program at Northside Hospital Cancer Institute, about what survivorship really looks like after a stem cell transplant. The central message is that survivorship is not a finish line. It is a transition into a new normal. Many patients expect life to return to the way it was before diagnosis or transplant, but recovery usually feels slower, messier, and more emotional than that. Fatigue, side effects, fear, and frustration can last for months, and that does not mean something is wrong. It means recovery is still happening. We also focus on how important it is to set realistic expectations. Christy explains that early struggles do not define long term outcomes. A setback in the first weeks or months after transplant does not mean a patient will not go on to live a full and meaningful life. Recovery takes patience. Small wins matter. Walking to the mailbox, cooking a meal, or getting through a day with a little more energy can be major milestones. Over time, those moments add up. Another major theme is emotional recovery. We talk about the fear of recurrence and the challenge of learning what is normal after treatment versus what should be reported to a doctor. That education helps people feel more confident and less trapped by fear. We also touch on how easy it is to forget that some aches and pains may simply come with getting older, not always with cancer. That perspective can be grounding. Other survivors can be a valuable information resource, too. Support comes up again and again throughout the conversation. Caregivers remain important in survivorship, but their role changes. Friends, peer support, support groups, podcasts, and survivorship communities all help patients feel less isolated. Christy emphasizes the value of honesty and vulnerability, especially in telling people what kind of support is needed on a given day. Some days call for celebration. Some days call for rest. We also talk about the tension between wanting to get back to life and needing to stay safe. Many survivors ask when they can return to work, travel, attend church, or see family. That desire is a good sign. It shows hope. At the same time, it takes guidance from the healthcare team to know when and how to widen that protective bubble. The episode ends on a hopeful note. Christy shares that she does not think of one survivor story. She thinks of many faces. She describes the joy of seeing patients return months later looking stronger, brighter, and more like themselves. That image captures the heart of the episode. Survivorship is hard, but it is also full of possibility, growth, connection, and life after transplant. More: Northside Hospital Cancer Institute Blood & Marrow Transplant Program — https://www.northside.com/services/cancer-institute/cancer-treatment-options/blood-marrow-transplant-program Northside Hospital Cancer Institute Blood Cancer Program — https://www.northside.com/services/cancer-institute/cancer-programs/blood-cancer-program National Bone Marrow Transplant Link (nbmtLINK) — https://www.nbmtlink.org/ Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Introduction (00:40) Meet Christy Donovan (01:42) Survivorship as a transition (03:00) The role of caregivers and support after transplant (03:38) Early struggles vs long term outcomes (05:41) Emotional impact and fear of recurrence (07:02) Learning what is normal and what is not (07:55) Support groups, healing arts, and community (08:44) Being honest with friends about what you need (09:34) Managing energy and celebrating small wins (11:02) Patience, hope, and finding your people (13:15) Common questions in early survivorship (14:27) Expanding the protective bubble (15:20) The many faces of survivorship (17:03) Final encouragement and close National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today, Peggy talks with Daniel Gaylor, LCSW, OSW-C, ACHP-SW, and a social work supervisor at Moffitt Cancer Center, about what happens after patients and caregivers get through the intense treatment period and begin asking, “Now what?” Daniel explains that recovery does not mean life snaps back to normal. Survivorship brings fear, relief, hope, uncertainty, and exhaustion all at once. Those reactions are normal, and they deserve to be named. Daniel explains why post-traumatic stress disorder (PTSD) can show up after transplant. A transplant is not a routine treatment. It can involve long hospital stays, isolation, major physical side effects, and real fears about survival. When patients return for follow up visits, they may be brought back emotionally to those difficult hospital days. This can make survivorship feel complicated, even when the transplant was successful. Another key theme is slowly letting go. Patients may feel afraid to go out, socialize, eat in a restaurant, drive, or return to activities they once enjoyed. Daniel encourages survivors to start small and to be fair to the situation. It is easy to imagine the worst case. But it also helps to keep yourself honest - say out loud what could happen if things go well. The episode also addresses the “strain of worry.” Daniel describes signs of anxiety and depression, including sleep problems, racing thoughts, trouble concentrating, irritability, sadness, appetite changes, and not wanting to do things that usually bring joy. He reminds listeners that difficult days do not mean failure. Survivors should be able to say, “Today is not my best day,” and ask for help. Peggy and Daniel also talk about toxic positivity. While loved ones often mean well, phrases like “you're lucky to be alive” can minimize a survivor's fear or pain. Daniel encourages honest communication. Patients can thank loved ones for their support while also explaining what would help more. Social connection is another major part of healing. Daniel urges survivors and caregivers to increase connection and reduce isolation. A quick text, a short call, a support group, or a shared conversation can make a real difference. Peggy highlights programs where survivors can meet others who understand graft versus host disease (GVHD) and transplant recovery. Daniel closes with the idea of building a “tool belt.” Each person needs practical coping tools, whether that is a friend, music, journaling, counseling, mindfulness, a book, or a favorite place to reset. Caregivers need their own tool belts too. Transplant affects the whole support system, and survivorship works best when people communicate, ask for help, and remember they are not meant to do this alone. Links: Elephants and Tea: https://elephantsandtea.org/ BMT InfoNet: https://bmtinfonet.org/ Blood Cancer United: https://bloodcancerunited.org/ Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Intro (01:01) Normalizing emotional reactions during recovery (04:22) PTSD after transplant and why it matters (08:59) Slowly letting go after transplant (13:12) Facing the worst case and choosing to move forward (13:53) The strain of worry and mental health red flags (19:31) Toxic positivity and the power of validation (20:26) How to talk with loved ones who are trying to help (22:39) Social health, connection, and friendship (26:43) Support groups, GVHD, and feeling understood (28:07) Building a survivorship "tool belt" (33:08) Why transplant never fully “stops” (36:39) A patient story about resilience and asking for help National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Marrow Masters, we speak with Stephanie Chuang, founder and chief storyteller of The Patient Story. Stephanie shares how her life changed at 31, just two months before her wedding, when she was diagnosed with lymphoma. At the time, she was working as a TV news reporter in San Francisco and had been explaining away symptoms like fatigue, bloating, and a strange cough. A same day doctor's visit led to blood work, an x-ray, an emergency CT scan, and then the call that confirmed lymphoma. Stephanie talks about the shock of diagnosis and the fear that followed. She also shares how much it mattered to have people around her who understood how to navigate the health care system. A family friend who was a doctor helped her get into care quickly, showed her what steps to take, and became a human compass during a frightening time. That experience stayed with her. It helped shape the reason she later created The Patient Story, so others would not have to feel so alone after diagnosis. The conversation then moves into survivorship and the emotional whiplash that can happen when treatment ends. Stephanie explains that hearing “no evidence of disease” was a huge relief, but it did not mean life went back to normal. She felt grateful, but she also felt lost. Her identity as a journalist, fiancé, daughter, sister, and busy person had been shaken. She could not simply return to the same pace or the same version of herself. Stephanie also talks about scanxiety and the surveillance cycle. She describes how difficult it can be to move from frequent monitoring to longer gaps between appointments. Graduating from three month checks to six month checks can feel like progress, but it can also feel scary. She explains that giving herself permission to feel anxious, without adding shame, helped her cope. We also talk about the phrase “the new normal” and the late effects that can follow intense treatment. Stephanie shares that survivorship requires more support than many people realize, especially when patients move from oncology care back to primary care. She emphasizes the importance of meeting people where they are, validating their fears, and helping them feel less alone. The episode closes with Stephanie's message to newly diagnosed patients: you are not alone, your questions matter, and you deserve to speak up in the doctor's office. The Patient Story exists to share honest, hopeful stories that help people find connection, information, and courage. Links: The Patient Story: https://thepatientstory.com/ Bag It Cancer: https://bagitcancer.org/ Escape to THRIVE: https://escape4advocates.org/ Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Intro (01:34) Stephanie begins her cancer story (06:01) Navigating the medical system with help from a doctor friend (07:16) Hospital testing, biopsy, and the idea behind The Patient Story (08:35) Moving into survivorship (10:14) Identity, work, and life after cancer (13:03) Scanxiety and the surveillance cycle (16:31) Survivor guilt and transitioning back to primary care (17:47) Identity loss after leaving a news career (23:21) The phrase “the new normal” (26:36) Meeting people where they are in survivorship (28:16) The power of patient storytelling (28:41) Caregivers, care partners, and family support (30:20) Advice for newly diagnosed patients National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Marrow Masters, we talk with Adam Claxton, a British acute myeloid leukemia (AML) survivor who was diagnosed in 2024 and received a transplant in December 2024. He shares what early survivorship really feels like, especially the part no one prepares you for. Once treatment slows down, there is a gap between being a patient and figuring out who you are in the world again. Adam explains that around the 100 day mark, he felt dropped out of the system and forced to ask where he fit, what had changed, and who he was becoming after transplant. We also discuss graft versus host disease (GVHD) and how Adam reframes it. He calls it the price he pays for leukemic protection. That shift in perspective helps him see chronic GVHD not only as a complication, but also as evidence that the donor cells are doing their job. He is honest that it can be difficult physically and mentally, but he chooses to view it as part of survival and a sign that his body is being protected. A major focus of the conversation is mindset. Adam talks about mindset as something we have to work on daily, just like updating a device. He believes our thoughts shape how we feel, behave, and respond, and that mental habits matter just as much as physical recovery. He also opens up about relapse, calling it an even harder battle than the initial diagnosis. What helps him move through it is staying connected to his reasons for going on, including his family, his purpose, and his desire to help more people with his voice and experience. The episode also looks at faith over fear. Adam says both fear and faith still take you through the day, so he would rather choose the path that gives him hope. That same thinking connects to what he calls the reset after transplant. He realized he could not simply return to the same life, work, and identity he had before cancer. His priorities had changed, and so had his sense of purpose. Instead of trying to recover the old version of himself, he began building a new one. On a practical level, Adam shares advice about routines, mindfulness, exercise, social media boundaries, and finding joy again in simple things. One of his best suggestions is to go back to the things you loved doing around age 12, because those activities often reconnect you with peace, play, and presence. He also speaks warmly about the importance of support, especially from his wife and children, while reminding us that caregivers carry their own emotional burden too. By the end, Adam leaves listeners with a clear message. Survivors need to be kinder to themselves, own their stories, and start sharing what they have learned. His closing affirmation says it best: we can, we will, we must. More: Adam's Book, Daddy's Magic Blood, on Amazon: https://www.amazon.com/Daddys-Magic-Blood-story-healing/dp/B0GLGXHGW6 Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Intro (01:52) The gap after treatment and early survivorship (03:52) Why survivorship can feel harder than treatment (07:24) Mindset and daily mental conditioning (10:23) Handling relapse and staying connected to purpose (13:20) Faith over fear (15:31) The post transplant identity reset (23:19) Social media, support, and emotional boundaries (26:50) The role of family and caregiver support (29:12) What survivors need more of (32:28) Final affirmation: We can, we will, we must National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Marrow Masters, Peggy Burkhard talks with caregiver Ashlee Cramer about what caregiving really looks like during cancer, bone marrow transplant, and survivorship. Ashlee shares the story of her son Michael, who was diagnosed in 2020 with hepatosplenic T-cell lymphoma. Their family had already lived through cancer once before, when Ashlee's husband Patrice was diagnosed with large B-cell lymphoma in 2014 and later died at home in hospice, surrounded by his family. Ashlee explains that caregiving is often misunderstood. Caregivers are not saints who always feel strong, positive, or ready. Many are scared, exhausted, grieving, and trying to manage jobs, children, finances, appointments, medications, and the emotional weight of watching someone they love suffer. She says caregivers often feel pressure to do everything alone, but that pressure can lead to burnout and isolation. The conversation focuses on the reality that caregiving is not always temporary or predictable. For Michael, treatment moved quickly from diagnosis to hospitalization to transplant. He received a stem cell transplant from an anonymous donor, went into remission, and then developed serious complications, including engraftment syndrome, acute graft versus host disease (GVHD) , and chronic GVHD. Ashlee says Michael is a miracle, and while GVHD remains part of his life, the key word is living. Ashlee also talks about mental health for caregivers. She names anxiety, depression, post-traumatic stress disorder (PTSD), burnout, and loneliness as common experiences. She points out that many cancer centers offer support for patients, but caregivers often have to search for help on their own. Support groups, virtual programs, and caregiver resources can make a major difference because connection helps people feel less alone. A central message of the episode is that caregivers need care too. Ashlee encourages caregivers to take small pockets of peace when they cannot take a full day away. A shower, a breathwork practice, a walk outside, a cup of coffee, or a short hug from another caregiver can help. She also reminds caregivers to accept help. A meal train, a friend waiting in the hospital lobby, or someone offering a few minutes of support can ease the load. The episode ends with hope. Ashlee talks about post-traumatic growth, or PTG, and the idea that people do not have to bounce back to who they were before trauma. They can bounce forward. Michael and Ashlee continue to advocate, share their story through their podcast Michael and Mom Talk Cancer, and remind other caregivers that they are not alone. Thanks to this season's sponsors, Incyte and Sanofi. (00:00 Intro (04:05) Misconceptions about caregiving and why caregivers are not saints (05:30) Why caregivers should not be expected to do everything alone (07:00) The pressure to “stay strong” and how it can isolate caregivers (09:49) The reality of caregiving and how much it affects mental health (12:03) Work, family, sacrifice, and the myth of balance (16:40) Caregiver anxiety, depression, PTSD, burnout, and the need for support (20:40) Finding small “pockets of peace” when a full break is impossible (23:10) What Ashlee wishes she knew earlier about speaking up and asking questions (24:59) Why accepting help matters and how a meal train supported her family (34:09) Post-traumatic growth and the idea of bouncing forward instead of bouncing back National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today, Peggy Burkhard talks with Dr. Amar Kelkar of the Dana-Farber Cancer Institute about the medical side of survivorship after bone marrow, stem cell, or CAR-T transplant. The conversation begins with the important shift from the urgent “save my life” phase to the longer “protect my health” phase. Dr. Kelkar explains that this transition often starts around the 100-day mark, though timing varies by transplant center, geographical region and patient needs. A major theme is the need to restart routine care that may have been paused during transplant. Dental care, dermatology, ophthalmology, and primary care all become important again. Dental visits are especially important because oral graft-versus-host disease (GVHD) can cause dry mouth, irritation, cavities, and other problems. Skin checks matter because transplant can increase the risk of skin cancers. Dr. Kelkar stresses annual dermatology visits, sun protection, SPF 50 or higher, protective clothing, and smart decisions about sun exposure. Fatigue is another central topic. Dr. Kelkar describes post-transplant fatigue as different from normal tiredness. It can feel deep, physical, and mental, and it may last for months or even years. He encourages patients to pace themselves, listen to their bodies, and build activity back slowly. Returning to work also needs to be individualized. Some patients work remotely during treatment, while others may need extended disability or a gradual return. The episode also covers immune recovery and repeat vaccinations. Dr. Kelkar explains that after transplant, the immune system has been reset, and many childhood vaccines need to be repeated. Most programs begin revaccination around six, nine, or 12 months, depending on immune suppression and other factors. He reassures listeners that many patients have fewer vaccine symptoms early on because their immune systems are still rebuilding. Dr. Kelkar also reviews long-term screening and prevention. Survivors need routine cancer screenings, including mammograms, colonoscopies, lung cancer screening when appropriate, skin exams, and monitoring for thyroid or other changes. Metabolic health is also important. Steroids can affect blood sugar, transplant can change body composition, and quick weight loss often includes muscle loss. Nutrition support and exercise programs can help, and Peggy notes that Blood Cancer United offers nutrition services for patients and caregivers. Blood Cancer United's nutrition program provides free one-on-one consultations with oncology dietitians by phone or email. Bone health, hormone changes, sexual health, and early aging are also discussed. Dr. Kelkar explains that steroids, menopause, testosterone changes, vitamin D deficiency, and time indoors can affect bones. Many centers use DEXA scans and vitamin D supplementation. He also encourages patients to bring up sexual health concerns, including menopause symptoms, low testosterone, pain with intercourse, ulcers, or fear about resuming intimacy. The episode closes with practical advice for everyday life. Food restrictions often loosen around 100 days, but patients should reintroduce foods slowly and carefully. Raw foods, alcohol, tobacco, and inhaled smoke should generally be avoided, especially during the first year. Dr. Kelkar also emphasizes mental health support, counseling, and honest conversations with the medical team. Survivorship is a bumpy road, but the goal is to help patients regain control and thrive. Blood Cancer United Nutrition Offerings: https://bloodcancerunited.org/blood-cancer-care/adults/food-nutrition Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Intro (01:16) Moving from acute treatment to survivorship (02:17) Dental, dermatology, ophthalmology, and routine care (05:45) Fatigue after transplant versus normal tiredness (08:35) Pacing yourself and avoiding setbacks (10:26) Returning to work after transplant (12:24) Resetting the immune system and repeat vaccinations (16:07) Secondary malignancy prevention and cancer screenings (18:59) Sun protection and skin cancer prevention (20:23) Metabolic health, blood sugar, and weight management (23:58) Bone health, vitamin D, DEXA scans, and early aging (29:32) Sexual health and hormonal changes (32:43) Everyday living after transplant (36:07) Psychological and cognitive hurdles in survivorship (38:16) Pulmonary function tests and liver monitoring (40:42) Closing thoughts National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailSome of the most important cancer and autoimmune disease drugs in the world still require patients to sit in infusion chairs for hours - but that model may be about to change entirely.Matthew Huddleston is Chief Commercial Officer at Enable Injections ( https://enableinjections.com/ ), a medical device company focused on rethinking how large-volume biologic drugs are delivered to patients.Enable's core technology, the enFuse® on-body delivery system, is designed to shift certain therapies from traditional intravenous infusion to subcutaneous, wearable administration - potentially transforming treatment from something that requires a clinic visit into something that can be done at home, more comfortably and more conveniently.What makes this particularly interesting is where Enable sits in the broader biopharma ecosystem. The company is actively partnering with major pharmaceutical innovators including Sanofi, Roche, Incyte, and Viridian Therapeutics to support the transition of complex biologics into subcutaneous delivery formats.One of the clearest signals of momentum is that Sanofi's Sarclisa combined with Enable's on-body injector has been recommended for approval in Europe by the CHMP, with FDA review ongoing - highlighting that this is no longer theoretical innovation, but an emerging commercial pathway.Enable is also extending its platform through collaboration with Aptar Pharma and its digital health division, integrating companion software to support patients throughout therapy - bringing drug delivery closer to a connected care ecosystem, where device, data, and treatment adherence increasingly converge.On this episode we will unpack how this platform works, what it enables for pharma partners, and how wearable drug delivery could reshape the future of biologics.#biotech #medtech #drugdelivery #biologics #pharma #oncology #multiplemyeloma #medicaldevices #healthtech #wearabletech #subcutaneous #infusiontherapy #drugdevelopment #pharmaceuticalindustry #innovation #digitalhealth #enableinjections #sanofi #roche #incyte #clinicaltrialsSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of exciting advancements and strategic moves that are shaping the future of healthcare. Let's start with Pfizer's efforts in pneumococcal vaccination, a testament to the ongoing battle against Streptococcus pneumoniae. With their sights set on expanding protection and combating emerging health threats, Pfizer's initiatives reflect an industry-wide commitment to adapt to microbial challenges, potentially enhancing global public health outcomes. Their work underscores the crucial role vaccines play in preventing severe infections and maintaining public health. In other news, Parabilis Medicines is making strides by eyeing public markets to bolster its phase 3 tumor drug development. This move highlights the increasing reliance on public funding to advance late-stage clinical trials, which are essential for bringing new therapies to patients. Meanwhile, Lilly's acquisition of Engage for $202 million marks a significant expansion into non-viral DNA delivery systems. These systems could address traditional gene therapy challenges, promising more effective and safer genetic medicine options. Immunovant recently decided to discontinue its first-generation FcRn inhibitor after disappointing phase 3 results. This decision illustrates the unpredictable nature of drug development, where clinical evaluations often lead companies to reassess strategies based on trial outcomes. Such pivots are part and parcel of the rigorous scientific process that drives innovation forward. The integration of artificial intelligence in drug discovery is gaining momentum. Incyte's $80 million investment to expand its AI-driven partnership with Genesis is a clear indication of AI's growing importance in optimizing drug discovery. Similarly, Bristol Myers Squibb's collaboration with Anthropics Claude highlights a broader trend of leveraging AI across R&D processes to enhance efficiency and streamline operations. Additionally, Incyte's partnership with Edison Scientific to integrate Kosmos AI across R&D workflows exemplifies AI and machine learning's growing role in enhancing oncology drug discovery processes. Enter Oorja Bio, a newcomer focusing on idiopathic pulmonary fibrosis with a $30 million launch fund. Their novel approach to tackling this debilitating condition exemplifies the innovative spirit within smaller biotech firms aiming to address unmet medical needs. Oorja Bio's efforts are part of a larger movement in biotech where new entrants are making significant impacts by targeting specific diseases with fresh perspectives. On the regulatory front, Gilead has expanded its partnership with Korean manufacturer Yuhan through a $140 million deal for active pharmaceutical ingredients. This strategic move ensures robust supply chains amid evolving regulatory standards and market demands, underscoring the importance of global partnerships in maintaining drug availability and quality. Turning our attention to oncology, the American Society of Clinical Oncology (ASCO) 2026 conference is poised to be a significant event for industry professionals. The focus this year includes precision oncology and evolving trial designs, particularly for pancreatic cancer. The complexity of oncology studies demands tailored solutions for efficacy and regulatory compliance, pushing toward more adaptive and patient-centric trial designs. City of Hope's participation at ASCO emphasizes collaborative efforts in cancer research, combining cutting-edge science with comprehensive patient care to translate breakthroughs into tangible improvements in outcomes. Labcorp's involvement further underscores precision oncology's role through biomarker-driven trials and companion diagnostic development. The conversation at ASCO 2026 will also explore the future design of pancreatic cancer trials. By incorporating external controls and real-world data, researchers aim to streamline processes and expedite access to new therapies, acknowledging pancreatic cancer's unique challenges. In other significant advancements, UCB's Bimzelx showed superior efficacy over Skyrizi in treating psoriatic arthritis during a Phase 3 trial. As an IL-17A/IL-17F inhibitor, Bimzelx represents a promising biologic therapy option, potentially setting new standards in autoimmune treatment. Roche's voluntary license agreement with Medicines Patent Pool for Xofluza accessibility highlights efforts towards global health equity, ensuring essential medications reach low- and middle-income countries. Finally, financial movements such as Mentari Therapeutics' reverse merger raise substantial capital for neurological therapies, exemplifying ongoing investment confidence within the sector. These stories collectively illustrate an era marked by scientific innovation, strategic partnerships, and technological integration aimed at improving patient care and accelerating drug development pathways. As we continue to explore these advancements on Pharma Daily, stay tuned for more insights into how these developments shape our industry's future. That's all for today's episode of Pharma Daily. Thank you for tuning in as we navigate through these transformative times in pharmaceuticals and biotechnology.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest happenings shaping the landscape of this dynamic industry. The pharmaceutical and biotech sectors are navigating a complex landscape replete with scientific advancements and regulatory challenges. A significant legal development comes from Takeda, which faces an $885 million verdict in a landmark pay-for-delay antitrust case. This ruling highlights the intense scrutiny of pharmaceutical companies over antitrust regulations, with potential implications for drug pricing strategies and industry practices. The possibility of tripling damages under these laws could set a precedent affecting future business operations, as Takeda plans to appeal, underscoring the high stakes involved in such litigation. Meanwhile, on the regulatory front, the White House's decision to include 600 generic medications in the TrumpRx purchasing portal marks a strategic effort to improve drug affordability. While its overall impact remains uncertain, this initiative aims to bridge gaps in medication accessibility for cost-sensitive populations. Similarly, Roche's licensing agreement with the Medicines Patent Pool to allow generic versions of Xofluza in 129 developing countries is a noteworthy step towards enhancing global access to essential medicines. These efforts underscore ongoing attempts to address affordability and accessibility concerns on a global scale. In clinical developments, UCB's Bimzelx has shown promising results against AbbVie's Skyrizi in treating psoriatic arthritis, demonstrating a statistically significant reduction in disease activity compared to Skyrizi in a Phase 3b trial. With nearly half of the patients showing improved outcomes at week 16, Bimzelx is poised to become a competitive therapeutic option, potentially redefining treatment protocols for psoriatic arthritis. Novartis's termination of its contract with Chinese CDMO Porton Pharma Solutions due to regulatory issues underscores the challenges inherent in cross-border pharmaceutical partnerships. The $64 million legal claims looming over this decision highlight the financial and operational risks associated with international collaborations. Meanwhile, biopharmaceutical buyers are increasingly turning to artificial intelligence and local expertise to navigate rising licensing costs in China. Sanofi and Wave Life Sciences are making progress in addressing α1-antitrypsin deficiency (AATD), a genetic disorder that has witnessed limited therapeutic innovation for decades. Their efforts were highlighted at the American Thoracic Society meeting, showcasing ongoing attempts to bridge treatment gaps for rare diseases through next-generation approaches. Strategic investments continue to shape the industry, as evidenced by Lauxera Capital Partners' successful EUR520 million fundraising aimed at advancing healthcare technologies. Additionally, Merck's agreement to supply Keytruda for Exelixis' colorectal cancer trial exemplifies collaborative efforts crucial for advancing cancer research. These developments reflect an industry balancing innovation with regulatory compliance and market dynamics. Scientific progress is also evident in Relay Therapeutics' advancement with its PI3K inhibitor, which has shown promising Phase 2 data in treating blood vessel disorders. This underscores the potential of PI3K inhibitors to address unmet medical needs by targeting pathways significant in cancer and other diseases. The integration of artificial intelligence into drug discovery processes is another critical trend. Incyte's collaboration with Edison Scientific aims to enhance decision-making and streamline drug discovery, showcasing AI's potential to revolutionize R&D efficiency. However, persistent challenges remain as AI scales up but doesn't yet resolve clinical trial protocol issues fully. On the business front, Bristol Myers Squibb considers investing $1 billion in a Houston manufacturing plant, emphasizing strategic infrastructure investments crucial for meeting growing pharmaceutical demands. In drug approvals, AstraZeneca's Baxfendy has received FDA approval for treating uncontrolled hypertension by targeting aldosterone synthesis—offering a novel approach as a combination therapy. Moreover, Merck & Co.'s sacituzumab tirumotecan has achieved Phase 3 success in endometrial cancer trials, demonstrating superior survival outcomes compared to chemotherapy. This highlights the growing impact of targeted therapies in oncology and the ongoing shift towards precision medicine. Despite these positive developments, challenges persist. BioMarin Pharmaceutical's BMN 401 faced setbacks after missing key Phase 3 endpoints for skeletal healing in ENPP1 deficiency patients—highlighting complexities in rare disease drug development. In conclusion, these diverse developments reflect an industry steadfastly committed to advancing healthcare through scientific innovation while navigating regulatory hurdles and operational challenges. As these sectors evolve further, maintaining a balance between rapid innovation and rigorous oversight remains essential to ensuring impactful treatments reach patients worldwide promptly. Thank you for tuning in to Pharma Daily—stay informed and stay ahead of industry trends with us tomorrow!Support the show

Season 20 of the Marrow Masters Podcast, produced by the National Bone Marrow Transplant LINK, focuses on thriving in survivorship post-transplant. You'll hear from patients, caregivers, doctors and social workers as they share their best tips and practices. Season 20 of the Marrow Masters Podcast is sponsored by Incyte and Sanofi. Look for Season 20 on May 27, 2026. And be sure not to miss an episode! Follow our show for free on Apple, Spotify, YouTube, or wherever you're listening right now. National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This accredited continuing education program is supported by an educational grant from Blueprint Medicine. It provides timely and practical education on systemic mastocytosis (SM). To obtain CME credit, visit https://checkrare.com/learning/p-systemic-mastocytosis-recognition-diagnosis-and-clinical-management/SM is a rare, chronic disorder driven by aberrant mast cell accumulation across multiple organ systems. Although diagnostic criteria are well established, a recent natural history study found that the average time to diagnosis is nearly five years. This prolonged delay—largely due to limited awareness of SM and its early symptoms—often results in unnecessary disease progression and inappropriate treatment. To address this clinical gap, this activity, led by Daniel J. DeAngelo, MD, PhD, Chief, Division of Leukemia at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston, MA, provides an overview of the early signs and symptoms of SM, outlines the appropriate diagnostic criteria and tools, and reinforces the importance of timely referral and testing for these patients to be properly managed. Led by a clinical expert with experience diagnosing and treating patients with SM, this 45-minute CME program will highlight early signs of SM, outline diagnostic criteria and tools, and reinforce the importance of timely referral/testing. Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hematology, dermatology, gastroenterology, immunology, and family practice. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the early symptoms of systemic mastocytosis and its clinical relevance.Apply best practices to diagnose systemic mastocytosis more efficiently.FacultyDaniel J. DeAngelo, MD, PhDChief, Division of LeukemiaDana-Farber Cancer Institute,Harvard Medical SchoolBoston, MADisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. DeAngelo discloses the following relevant financial relationships with ineligible companies:Consultant: Amgen, Autolos, Blueprint Medicines, Incyte, Jazz, Novartis, Pfizer, and Takeda Research Support: AbbVie, Glycomimetics, Novartis, and Blueprint MedicinesData Safety Monitoring Board: Daiichi-SankyoOther Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2026. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Summary: In this episode of the Future of Dermatology podcast, host Dr. Faranak Kamangar sits down with Dr. Haley Naik, board-certified dermatologist, professor at UCSF, and Stanford and Harvard-trained expert, for a timely and eye-opening conversation on two major fronts: the rapidly evolving treatment landscape for Hidradenitis Suppurativa (HS) and the critical California state legislation that could reshape how dermatologists practice and how patients access care. Dr. Naik opens with exciting updates in the HS space, including the three currently FDA-approved therapies and two promising agents anticipated to cross the finish line by 2027. She also shares a major advocacy win: HS has been designated a highlighted research topic by the NIH across three institutes, opening a one-year funding window starting April 7, 2026 that researchers should act on now. The conversation then dives deep into the broken prior authorization system, with striking data points: 25% of dermatology visits require prior auth, 75% of denial letters have no listed decision maker, and the average dermatology practice spends $40,000 per year staffing for prior authorizations. Against this backdrop, Dr. Naik breaks down three California bills - two to support and one to oppose - that directly affect how dermatologists can care for their patients. Whether you're a dermatologist, researcher, or patient advocate, this episode is packed with actionable information, from NIH grant deadlines to how to contact your state representative before late June voting deadlines. Learn more and take action: AB539 (prior authorization reform): https://legiscan.com/CA/bill/AB539/2025 SB895 (California Science and Health Research Bond Act): https://lnkd.in/gTjXXxtU Find your California representative to advocate for these bills: https://findyourrep.legislature.ca.gov/ Information about the May 4th Rally for California Science: https://www.fundcascience.org/rally

Brückenstraße in Wetzlar droht lange Sperrung, Privatschule will christuszentrierte Bildung in Lahn-Dill und an der Uni Siegen öffnet das Forschungszentrum „Incyte“. Das und mehr heute im Podcast. Alle Hintergründe zu den Nachrichten des Tages finden Sie hier: https://www.mittelhessen.de/lokales/lahn-dill-kreis/wetzlar/brueckenstrasse-in-wetzlar-droht-lange-sperrung-5645829 https://www.mittelhessen.de/lokales/lahn-dill-kreis/landkreis-lahn-dill/privatschule-will-christuszentrierte-bildung-in-lahn-dill-5619941 https://www.mittelhessen.de/lokales/lahn-dill-kreis/wetzlar/verkehrsversuch-schillerplatz-ist-fuer-autos-dicht-5650041 https://www.mittelhessen.de/lokales/lahn-dill-kreis/wetzlar/eiszeit-kommt-nach-wetzlar-filiale-eroeffnet-im-sommer-5633897 https://www.mittelhessen.de/lokales/kreis-siegen-wittgenstein/siegen/an-der-uni-siegen-oeffnet-das-forschungszentrum-incyte-5646620 Ein Angebot der VRM.

R&D teams are starting to advance AI capabilities faster than they can translate them into measurable business value, creating mounting friction between scientific progress and operational reality. In this episode, Aziz Nazha, Global Head of AI Innovations Institute at Incyte Pharmaceuticals, examines how culture, talent, infrastructure, and expectation‑setting determine whether AI meaningfully improves drug discovery and development. He highlights the practical shifts required — from redesigning workflows to disciplined upskilling and targeted validation cycles — to ensure AI adoption accelerates cycle times rather than getting stalled by organizational bottlenecks. This episode is sponsored by Deloitte. Learn how brands like Deloitte work with Emerj and other Emerj Media options at go.emerj.com/partner

In this episode of ASTCT Talks, host Corey Cutler, MD of Dana-Farber Cancer Institute and Harvard University sits down with Nosha Farhadfar, MD, medical director of research for Sarah Cannon Research Institute's transplant and cellular therapy program at Methodist Healthcare, and Pooja Khandelwal, MD, an associate professor within the division of bone marrow transplantation at Cincinnati Children's Hospital Medical Center, to discuss adult and pediatric treatment perspectives for cGVHD.Tune in for a conversation that covers:Adult and pediatric cGVHD treatment approaches,including frontline choices and the selection and effectiveness of medications.Expert practice experiences for use in cGVHD treatment.New therapeutics the experts are looking forward to in cGVHD treatment. This episode was made possible thanks to a grant from Incyte.

What does it take for a treasurer to earn - and protect - credibility with boards, rating agencies, and banking partners during billion-dollar transactions?In this episode, we explore how treasury leaders like Stephen Kaufhold, Vice President & Treasurer at Incyte, build trust when the stakes are highest.Stephen Kaufhold returns to the show, now serving as Vice President & Treasurer at Incyte. When he last appeared, he was SVP & Treasurer at Allergan, leading treasury through significant capital markets activity and transformation. Since then, he has continued to navigate change at scale, bringing experience across financial services, telecom, and pharmaceuticals.In this follow-up conversation, Stephen reflects on his transition from Allergan to Incyte and shares how treasury builds and sustains credibility during defining corporate moments.We discuss capital allocation in pharma, managing leverage through large-scale transactions, and staying strategically relevant in an evolving financial landscape. Stephen also outlines how treasury professionals can deliberately build the exposure, skills, and judgment required to lead at the highest levels - from rating agency presentations to boardroom financing decisions.What We Cover in This Episode:Transitioning from Allergan to Incyte and navigating corporate transformationFinancing multi-billion-dollar acquisitions and divestituresPresenting capital structure strategies to boards and audit committeesBuilding and maintaining credibility with rating agenciesCapital allocation priorities in pharma: R&D, business development, debt reduction and buybacksOperating in both investment-grade and non-investment-grade environmentsDeveloping and mentoring treasury teams for long-term successThe importance of broad treasury exposure across cash management, capital markets and securitizationNavigating compressed deal timelines and capital markets volatilityThe evolving impact of AI, crypto, and cybersecurity on treasuryYou can connect with Stephen Kaufhold on LinkedIn.---

On this episode of The Menopause and Cancer Podcast, we're marking Anal Cancer Awareness Day (21 March) by shining a light on a cancer that is often misunderstood, stigmatised, and rarely talked about.Anal cancer is caused by HPV, just like cervical cancer, yet it doesn't receive the same awareness or open conversation. It might not feel as “pink” or as socially comfortable to talk about as breast cancer. It's not a cancer that gets glossy campaigns or big awareness drives. There's often stigma. There's embarrassment. There's silence.And that silence can leave people feeling incredibly alone.I'm joined by Ali, who shares her honest experience of being diagnosed with anal cancer; what treatment involved, the physical and emotional impact, and how it affected her confidence, menopause and sexual wellbeing.We also explore an important question: can treatment for anal cancer induce menopause?Pelvic radiotherapy and chemotherapy can affect ovarian function, sometimes triggering sudden or early menopause. We discuss what that means, and whether HRT or local oestrogen may be options.This episode is about inclusion.It's about making sure everyone — regardless of cancer type — feels seen in menopause conversations.If you've ever felt that your cancer isn't the “right” kind to talk about, this episode is for you.Episode Highlights:00:00 Introduction04:33 Cancer Diagnosis: Fear and Isolation12:15 "Stage 3 Cancer Challenges"14:32 "Breaking Stigma Around Cancer"23:22 "Menopause, HRT, and Cancer Journey"27:07 Burnout, Anxiety, and Menopause Journey30:36 "Pelvic Radiotherapy: Long-Term Impacts"36:01 "Barbie Butt: Finding Joy Amid Struggles"41:38 "Menopause, Cancer, and Support Gaps"About our guest Ali:Ali Stripling is a qualified Menopause Wellness Practitioner who was diagnosed with Stage 3 anal cancer in October 2024. She now speaks in workplaces about menopause, cancer and life in remission. Ali is also the author of #TweakAWeek, a practical framework helping perimenopausal women make positive changes without overwhelm. https://www.linkedin.com/in/alistripling/ Links:Macmillan Anal Cancer Support Forum: https://community.macmillan.org.uk/cancer_types/anal-cancer-forumThe Farrah Fawcett Foundation https://thefarrahfawcettfoundation.org/This podcast episode was supported by an unrestricted grant from Incyte Biosciences. Incyte had no involvement in the development, content, or editorial review of the activities associated with this initiative.Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.We start with a significant personnel change at the FDA, where Vinay Prasad, M.D., is set to depart by the end of April. Known for his contentious interactions with the biopharma industry, particularly concerning vaccines and cell and gene therapies, his departure may signal shifts in regulatory priorities and approaches. Industry stakeholders are closely watching how his exit will affect upcoming decisions and relations between regulatory bodies and biopharma companies.In a strategic collaboration, Novo Nordisk and Hims & Hers have settled their public disputes by agreeing to distribute Novo's Ozempic and Wegovy through Hims' telehealth platform. This partnership highlights the increasing importance of digital health platforms in expanding medication access, particularly for chronic conditions like obesity and diabetes. This trend reflects a broader movement where legacy pharmaceutical companies are turning to digital avenues to enhance patient reach.On the clinical trial front, Ipsen has decided to halt the development of its lymphoma drug Tazverik after safety concerns were raised by an independent data monitoring committee. This decision underscores the rigorous safety standards in place for clinical trials and the ongoing challenge of balancing potential therapeutic benefits against safety risks. Similarly, Roche's oral SERD giredestrant failed to meet its primary endpoint in a phase 3 trial for first-line breast cancer treatment, raising questions about the limits of selective estrogen receptor degraders despite previous successes in adjuvant and second-line settings. The complexity of translating promising mechanisms into consistent clinical outcomes across different stages of treatment is highlighted here.Regulatory challenges remain a significant theme, with Novo Nordisk's Indiana plant facing scrutiny that led to the FDA rejecting Incyte's application for Zynyz as a first-line treatment for non-small cell lung cancer. This incident underscores how manufacturing issues can heavily impact drug approval processes and highlights the critical nature of compliance with regulatory standards.In terms of new drug approvals, Bristol Myers Squibb has received FDA approval for Sotyktu, a first-in-class oral TYK2 inhibitor for treating psoriatic arthritis. This approval not only broadens treatment options for patients but also reinforces the ongoing trend towards developing targeted therapies with novel mechanisms of action. Additionally, Bristol Myers Squibb is gaining momentum with its cereblon E3 ligase modulator (celmod), mezigdomide, achieving statistically significant improvement in progression-free survival among multiple myeloma patients in a Phase 3 trial. This success solidifies BMS's position in hematologic oncology and demonstrates the potential of targeted protein degradation as a therapeutic strategy.The industry is also witnessing significant financial transactions and restructuring efforts. Lonza's decision to sell a majority stake in its capsule business to Lone Star Funds for $3 billion reflects strategic realignments as companies focus on core competencies while leveraging partnerships to optimize business operations.Meanwhile, regulatory scrutiny persists as Democratic lawmakers are investigating 11 pharmaceutical companies regarding their pricing agreements under the previous administration's "most favored nation" clause. This inquiry aims to understand whether these deals have indeed resulted in cost savings for Medicaid, highlighting ongoing concerns about drug pricing transparency and affordability.In another strategic move aimed at bolstering innovation, Regeneron reported promising results from a phase 3 trial conducted by its Chinese partner on a drug mirroring Zepbound's efficacy in obesity treatmenSupport the show

In this final episode, we examine how academia and industry work together to advance research and improve patient outcomes. The conversation highlights real‑world examples of shared data, translational science partnerships, diagnostic insights, and coordinated patient care. Listeners gain a deeper understanding of how combined expertise strengthens clinical trials and expands access to innovative therapies. This independent medical education program is supported by Incyte. Click here for a complete list of disclosures.

Episode 2 explores how private‑practice and industry‑run clinical trials bring efficiency, flexibility, and broader patient access to the research landscape. Our guests discuss the financial and scientific motivations behind industry partnerships, the strengths and trade‑offs of private sites, and how these settings support large, fast‑moving studies. Rare‑disease trials, PK designs, and investigator‑initiated research are highlighted as key collaborative touchpoints.This independent medical education program is supported by Incyte.Please click here for a complete list of disclosures.

This episode breaks down the foundations of academic clinical research, from how studies are conceived and funded to how protocols ensure rigor, consistency, and patient safety. Listeners learn about the roles of sponsors, CROs, IRBs, and research teams, as well as the advantages and challenges of conducting trials in academic settings. This independent medical education program is supported by Incyte.Please click here for a complete list of disclosures.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's episode, we delve into the dynamic landscape of these industries, exploring ambitious strategic plans, regulatory hurdles, scientific breakthroughs, and emerging trends that are shaping the future of healthcare.Let's begin with AstraZeneca, which has set an ambitious target to achieve $80 billion in revenue by 2030. This goal reflects their intention to bring over 25 blockbuster drugs to market, underscoring a commitment to innovation and expansion in their therapeutic portfolio. The focus on cutting-edge research is not just a strategy for growth but also a sign of the broader industry trend where large pharmaceutical companies pursue high-value targets to strengthen their market positions. AstraZeneca is also making strides in the weight-loss market with its new candidate elecoglipron, undergoing an extensive late-stage program to evaluate its efficacy as a monotherapy and in combination treatments for various indications. This development positions AstraZeneca competitively in the burgeoning sector, offering a novel therapeutic option for obesity management.Meanwhile, CSL Limited is undergoing a leadership transition. CEO Paul McKenzie has stepped down under pressure, and Gordon Naylor has been appointed as interim chief. This change highlights the critical role of strategic leadership in navigating industry challenges and maintaining growth trajectories amidst a rapidly shifting market landscape.In a display of financial success, Novartis reported a record-breaking performance for 2025. This achievement led to a 30% increase in CEO Vas Narasimhan's compensation, reaching $32 million. The company's robust financial health is attributed to advancing innovative treatments targeting unmet medical needs, emphasizing how achieving innovation milestones can significantly enhance corporate valuation and leadership rewards.Incyte is preparing for the patent expiration of its blood cancer drug Jakafi in 2028 by focusing on Opzelura, a topical cream that has witnessed a 33% sales increase from the previous year. With sales reaching $678 million, Opzelura's success highlights Incyte's strategic pivot to diversify its product offerings and mitigate risks associated with patent cliffs. This exemplifies how companies must continuously innovate and adapt to maintain competitive advantages.Moderna has entered into a long-term agreement with Mexico to ensure local mRNA vaccine supply through technology transfer to Laboratorios Liomont. This partnership extends Moderna's global footprint and underscores the critical role of mRNA technology in pandemic preparedness and vaccine accessibility, reinforcing its transformative impact on public health strategies.Regulatory landscapes have also seen notable activity. The FDA issued untitled letters concerning potentially misleading drug advertisements from companies like Novo Nordisk, Argenx, and Sobi. Such actions emphasize regulatory vigilance in marketing practices. Additionally, Lilly's Kinsunla failed to secure approval in Scotland, while Regenxbio faced rejection for its gene therapy for Hunter syndrome. These regulatory hurdles highlight the rigorous oversight pharma companies face and the complex pathways drugs must navigate before market approval.Collaborations within the industry are proving crucial for innovation. Merck's collaboration with Calla Lily Clinical Care aims to enhance delivery systems for vaginal therapeutics. Similarly, Bristol Myers Squibb's partnership with Evinova focuses on integrating AI into clinical development processes. These alliances reflect an industry-wide emphasis on leveraging technology to improve drug delivery efficiency and streamline clinical trial operations.Shifting our focus now to scientific advancements and clinical trial results that aSupport the show

Another affordability push from the White House, as the Trump administration targets power costs associated with the AI buildout. The companies in focus, and how they could help offset the electricity costs. Plus The latest from JPMorgan's Health Care conference. What one bipharma CEO sees in store for the industry. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

Alexis Garcia and Ken Shreve analyze Tuesday's market action and discuss key stocks to watch on Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we delve into the year 2025, it's clear that the pharmaceutical and biotech industries have been navigating a complex landscape filled with both challenges and remarkable advancements. Despite regulatory uncertainties and broader economic fluctuations, the FDA approved 55 new treatments and vaccines this year. Although this figure represents a slight decline from previous years, it underscores the sector's resilience and steadfast commitment to innovation even amid external pressures.One significant development in oncology comes from Incyte, which is advancing its application for FDA approval of a seven-drug Monjuvi regimen as a first-line treatment for diffuse large B-cell lymphoma. This move is backed by positive Phase 3 trial results, highlighting Monjuvi's potential to enhance treatment options for this aggressive cancer type. However, Incyte may face hurdles in gaining regulatory approval and achieving commercial success, reflecting the competitive nature of oncology therapeutics.In obesity management, Novo Nordisk introduced its once-daily Wegovy pill in the U.S., marking a milestone in the field. Priced at $149 per month for cash-paying patients with potential discounts for those insured, Wegovy's launch could shift market dynamics significantly by offering a more accessible treatment option. This aligns with the growing global focus on obesity as a critical public health issue.The industry also saw substantial investments to bolster manufacturing capabilities. Daiichi Sankyo announced plans to invest $1.9 billion to expand Enhertu production facilities across countries such as the United States, China, Japan, and Germany. This strategic move aims to strengthen supply chain robustness and meet anticipated demand for Enhertu, a pivotal player in cancer therapeutics. Meanwhile, economic pressures are palpable as drugmakers raised prices on over 350 products at the start of the year, surpassing previous years' increases. This reflects ongoing tensions around drug pricing policies and affordability, posing challenges for industry stakeholders and patients alike.The labor landscape within biopharma has been affected as well, with layoffs increasing by 16% year-over-year in 2025. These reductions highlight ongoing cost-cutting measures amid financial uncertainties and strategic realignments within companies. Yet, strategic partnerships continue to shape research and development efforts, particularly in autoimmune diseases. Sanofi's collaboration with AI biotech Earendil Labs could potentially reach $2.5 billion, emphasizing the increasing role of artificial intelligence in drug discovery and development processes. These collaborations are poised to accelerate advancements in personalized medicine and innovative therapeutic approaches.Regulatory activities have also seen notable developments this year. GSK's Nucala received approval for treating COPD in China, expanding its therapeutic scope beyond asthma. This regulatory progress signifies opportunities for existing drugs to access new markets and indications. However, the National Institutes of Health faced leadership challenges with the departure of its National Institute of Neurological Disorders and Stroke director. This adds to a series of leadership changes across NIH institutes, raising concerns about stability within this pivotal organization responsible for advancing medical research.Turning now to significant scientific advancements and clinical trials, promising results emerged from studies focused on cellular energy boosters aimed at treating Alzheimer's disease. A molecule that restores cellular energy was shown to reverse cognitive decline in mice with advanced Alzheimer's, suggesting a potential new class of therapeutics for this debilitating condition. Support the show

This is part three—and the final installment—of our series on complementary and alternative medicine in pediatric dermatology. In this episode, we turn our focus to the future, examining key research gaps, promising areas for investigation, and opportunities for collaboration. Dr. Peter Leo and Dr. Larry Eichenfield share their perspectives on where integrative approaches may intersect with advancing science, and how curiosity, rigor, and innovation can help move the field forward.Special thanks to Incyte for supporting this independent medical education program.Tell us about yourself by filling out this 1-question survey.

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDSAbstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDSAbstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDSPresenter: Rami Komrokji, MDSenior Member, Vice ChairSection Head – Leukemia and MDSDepartment of Malignant HematologyH. Lee Moffitt Cancer CenterProfessor of Oncologic SciencesUniversity of South FloridaTampa, FloridaContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program: https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This is part two of our conversation on complementary and alternative medicine in pediatric dermatology. While these approaches may offer benefits, they can also carry risks—especially when misinformation spreads quickly online. In this episode, Dr. Peter Leo and Dr. Larry Eichenfield explore how pediatric dermatologists can assess safety, address popular but unproven therapies, and support families in making informed decisions, all while maintaining strong, trusting clinical relationships.Special thanks to Incyte for supporting this independent education program.Tell us about yourself by filling out this 1-question survey.

In today's episode, we're diving into a topic that's increasingly shaping conversations in pediatric dermatology clinics: complementary and alternative therapies. Families are asking about everything from dietary changes to topical botanicals—and clinicians are navigating how to respond with empathy, evidence, and safety in mind. Joined by Dr. Peter Leo and Dr. Larry Eichenfield, we'll explore why interest in these therapies is growing, which approaches families are using most, and how pediatric dermatologists can engage in these conversations thoughtfully and effectively.Thank you to Incyte for supporting this independent medical education program.Tell us about yourself by filling out this 1-question survey.

Alexis Garcia and David Saito-Chung walk through Monday's market action and discuss key stocks to watch in Stock Market Today Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLLBRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FLSTARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCLPresenter: Jeremy S. Abramson, MD, MMScProfessor of MedicineHarvard Medical SchoolDirector, Center for LymphomaMass General Brigham Cancer InsBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/4aqMobZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we speak with Synary Be, a resilient survivor of acute myeloid leukemia (AML), who shares her powerful journey of enduring three bone marrow transplants over eight years. Diagnosed suddenly in March 2017, Synary's story begins with a high fever that led to a shocking diagnosis: 93% leukemia. From that point on, her life transformed into a series of hospital stays, treatments, and moments that tested her strength and spirit.We learn how her first transplant involved two umbilical cord donors, one from the U.S. and another from Singapore. When that failed to graft, her younger brother flew from Australia to donate for her second transplant—a 50% match. After two years in remission, she relapsed again and required a third transplant, this time from her older brother, right in the midst of the COVID-19 pandemic. With travel restrictions in place, the donor cells had to be processed remotely and shipped to Stanford, showcasing the remarkable role of medical technology in saving lives.Despite being given only a 50% chance of survival for her third transplant, Synary put her trust in her doctors. Though she relapsed again, she now maintains remission through chemo pills. With no long-term data available for this new medication, she continues treatment cautiously and with optimism, trusting in the advancement of medicine.Synary spends some time opening up about the chronic graft-versus-host disease (GVHD) that followed her transplants. She explains its impact on her lungs, eyes, mouth, nails, and skin, detailing both the physical symptoms and the treatments that have helped her reclaim daily life. From scleral lenses to serum tears, to pulmonary rehab and steroid creams, she educates us on the challenges and management of GVHD.Beyond the physical toll, Synary discusses the mental health struggles tied to long-term illness—particularly anxiety from repeated hospitalizations. She emphasizes the importance of therapy, meditation, support groups, and the courage to seek help. Her words serve as a reminder that managing chronic illness includes caring for both mind and body.Synary's story wouldn't be complete without acknowledging her support system. Her husband, who acted as her full-time caregiver through 300 cumulative days of hospitalization, and her three children, endured major sacrifices. Friends and community support filled in the gaps, underscoring that no one should navigate transplant recovery alone.Even in the face of isolation, fatigue, and anxiety, Synary finds joy in simple pleasures: watching Christmas movies, going for walks, and spending time with family. Her message is clear—life is still good. And GVHD, while challenging, cannot take away her joy.Calm App — https://www.calm.comThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 - Introduction to Synary Be01:20 - AML Diagnosis and First Transplant03:10 - Transplants and Donor Challenges04:06 - Relapses and Chemo Maintenance06:44 - Living with GVHD12:15 - GVHD Symptoms and Treatments13:40 - Support System and Caregiving15:34 - Isolation After Transplants16:38 - Mental Health & Anxiety19:03 - Coping and Finding Joy20:36 - Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we sit down with Dr. Joseph Pidala from the Moffitt Cancer Center to discuss chronic graft-versus-host disease (GVHD), a complex condition affecting many stem cell transplant survivors. We focus on the latest prevention strategies, treatment innovations, and the critical role that clinical trials continue to play in advancing care.We begin with promising news around prevention. Dr. Pidala shares data from the BMT CTN 1703 trial, which compared conventional GVHD prevention to a newer approach using post-transplant cyclophosphamide (PTCy). This newer strategy significantly reduced the incidence of both acute and chronic GVHD, signaling a major step forward in preventing this debilitating condition.Despite advancements, many patients still experience chronic GVHD, which drives the need for new treatments. We explore several groundbreaking clinical trials that are rethinking traditional steroid-heavy treatment protocols. One study is testing Rezurock (Belumosudil) as a preemptive treatment during early symptoms, while another is investigating whether Jakafi (Ruxolitinib) can be used as a first-line treatment to reduce steroid reliance. These trials challenge old norms and aim to improve long-term outcomes.We also take a look at the four FDA-approved therapies currently available for steroid-refractory chronic GVHD: Ibrutinib, Jakafi, Rezurock, and the most recent addition, Axatilimab (Niktimvo). These drugs, each with different mechanisms and side effects, give patients and clinicians more flexibility than ever before. We touch on other widely used therapies like ECP (photopheresis), which, while not FDA-approved, remain an important part of care.Patient involvement is a key theme throughout. Dr. Pidala emphasizes that progress would be impossible without those who enroll in clinical trials, sharing inspiring examples of patients who benefited from early access to now-approved drugs. He encourages patients to advocate for themselves and speak up about symptoms, improvements, or quality of life changes. Patient-reported outcomes are becoming standard in trials, offering critical insight into treatment success from the patient's perspective.Dr. Pidala also highlights the importance of addressing GVHD holistically. Beyond core treatments, supportive care—including help with dry eyes, itching, joint mobility, pain, and mental health—is crucial to improving day-to-day life. He stresses that long-term recovery is possible and shares a moving story of a young woman with severe GVHD who, through persistent treatment, regained functionality and returned to a fulfilling life.We close with advice for patients: be proactive, informed, and open to trial participation. And when seeking information on trials, always start by asking your clinical team—they'll know what's available and suitable for your specific situation. Above all, Dr. Pidala leaves us with a message of hope—there's real progress being made, and the future looks brighter than ever.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Dr. Joseph Pidala01:21 – New GVHD Prevention Approaches02:44 – Why Clinical Trials Matter03:22 – Challenging Steroid-Based Treatment Norms06:14 – Timeline for New Treatment Results07:02 – FDA-Approved Drugs for Chronic GVHD09:09 – Individualized Treatment Approaches10:69 – The Role of Patient-Reported Outcomes13:44 – Symptom Management and Supportive Care15:20 – Addressing Mental Health in GVHD17:30 – Inspirational Patient Story21:12 – Advice for GVHD Patients23:02 – How to Find Clinical Trials25:06 – Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we speak with Rebecca Heimsoth, a young mother and survivor of myelodysplastic syndrome who underwent a bone marrow transplant in April 2022. Diagnosed shortly after turning 33, Rebecca shares her deeply personal journey of navigating transplant recovery, chronic graft-versus-host disease (GVHD), and parenting two small children. Her story is one of resilience, support, and a constant fight to reclaim her life after cancer.We begin by learning how Rebecca's transplant process unfolded with the support of her family. Her mother stepped in as her full-time caregiver while she temporarily relocated over an hour away from home for five months, separated from her children. Her youngest sister was a full match donor, which initially reduced concern for GVHD—until lung GVHD symptoms appeared five months post-transplant. This diagnosis triggered new fears, especially around survival, and marked the beginning of her chronic GVHD journey, which later expanded to include fascia involvement. Rebecca explains the physical and emotional toll—early menopause, chronic fatigue, cognitive effects, and mobility challenges.We discuss how she manages flare-ups with physical therapy, walking, stretching, and even cupping. Despite the physical setbacks, Rebecca remains actively involved with her family, thanks to a flexible job, long-term disability support, and a strong support system. Her husband takes on parenting duties when her health dips, and her kids have learned small routines to help protect her from illness, such as wearing masks and showering after school. These steps, while difficult, have helped them all cope as a unit.Rebecca also opens up about the mental health side of survivorship—dealing with PTSD, depression, and a sense of loss over her former self. She credits her psychologist, psychiatrist, and peer support groups as vital tools for managing the psychological weight. Online and in-person GVHD groups have connected her to other young adults navigating similar terrain, helping her feel less alone.Despite not returning to her full-time career, Rebecca is finding meaning in her part-time work and family life. Her goals have shifted—from professional advancement to simply watching her kids grow up. Whether it's family vacations or bedtime snuggles, she cherishes these moments. Her ultimate aim is to be present for her daughter's high school graduation in 2037. Every step forward, no matter how small, is part of the victory.Want to connect with a Young Adult Survivor Group? Find Kim on Instagram at @YourCancerBestie - http://instagram.com/yourcancerbestieThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Rebecca Heimsoth01:00 – Diagnosis at Age 33 and Initial Symptoms02:07 – Preparing for Transplant and Family Separation04:20 – Emotional Toll and Health Concerns06:20 – Importance of Physical Therapy and Walking06:53 – Balancing Flare-Ups, Appointments, and Parenthood08:20 – Role of Caregivers: Mom and Husband's Support09:43 – Kids' Resilience and Coping with Germ Concerns11:13 – Creative Ways to Explain Cancer to Children13:57 – Impact on Friendships and Social Life16:25 – Finding Online Support Networks and Groups17:43 – Meeting a Fellow Survivor in Person21:35 – Advice for Managing GVHD Symptoms23:16 – Navigating Nutrition with a Busy Family24:40 – Cognitive Health and Chemo Brain Hacks27:52 – Life After Transplant: Gratitude, Travel, and Parenting30:56 – Career Impact and Redefining Success32:23 – Living for the Milestones and Creating New Goals32:51 – Final Reflections and Words of Thanks National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we sit down with Sue Stewart, a 36-year survivor of acute myeloid leukemia (AML) and the founder of BMT InfoNet. Sue walks us through her transplant journey, beginning with a difficult diagnosis in the late 1980s and the grueling induction chemotherapy that followed. With limited treatment options, she opted for an autologous bone marrow transplant—a relatively new and uncertain procedure at the time. Despite the intense side effects, including confusion and delusions, Sue recovered and slowly rebuilt her life. Her story is one of strength and long-term resilience, shaped by medical challenges and a determination to help others facing similar paths.After surviving her transplant, Sue felt driven to understand her experience and quickly saw the gap in patient-centered information. A high-profile court case involving bone marrow donation misinformation pushed her to act. In response, she started a small newsletter to provide reliable, understandable transplant information. What began with 700 names (pre-Internet) grew rapidly and became BMT InfoNet, an organization that now supports over 20,000 people weekly with resources, educational content, and peer support.We explore how GVHD care has transformed over the decades. Sue outlines progress in diagnostics, treatment options, and the move away from long-term steroid reliance. Her organization has helped shift the focus beyond survival to long-term quality of life, leading to the creation of survivorship clinics and a deeper understanding of transplant-related complications.Sue introduces us to BMT InfoNet's key programs, including Caring Connections, which matches patients and caregivers with peers based on similar experiences. We also learn about their online, professionally moderated support groups, offered to different patient communities. These groups have been instrumental in helping individuals process their experiences and stay connected.The organization's educational materials and annual survivorship symposium continue to empower patients to become active members of their care teams. Sue emphasizes the importance of recognizing symptoms early, understanding treatment options, and advocating for proper care—especially for GVHD, which many local doctors may not fully understand.Finally, Sue shares the story of how one patient's experience with ocular GVHD and scleral lenses led to a wider medical breakthrough. It's a powerful reminder of how patients can change the landscape of care by sharing their stories. BMT InfoNet's mission remains clear: provide support, share knowledge, and give voice to those on the transplant journey.BMT InfoNet: https://www.bmtinfonet.orgContact Email: help@bmtinfonet.orgThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 - Introduction to Sue Stewart01:15 - Sue's AML Diagnosis and Transplant Story06:33 - Founding BMT InfoNet10:05 - Life Before the Internet: Lack of Resources12:43 - Progress in GVHD Treatment15:25 - Peer Support Through Caring Connections17:16 - Online Moderated Support Groups18:58 - Educational Resources on GVHD21:57 - GVHD Specialist Directory24:05 - Annual Survivorship Symposium26:17 - Financial Assistance for Patients27:39 - GVHD Wall of Hope and National GVHD Day30:01 - Final Story: How Patient Experience Changed GVHD Care National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Note: This episodes contains discussion and language of a sexual nature and may not be appropriate for all audiences.In this episode of Marrow Masters, we sit down with Dr. Christian Nelson, a psychologist at Memorial Sloan Kettering Cancer Center and an expert in psycho-oncology, to address a deeply personal yet often overlooked topic: male sexual dysfunction following cancer treatment. Together, we explore how treatments can impact not only physical function but emotional well-being, identity, and relationships.We start by acknowledging that sexual dysfunction is one of the most common side effects of cancer treatment, second only to fatigue. Yet, it's rarely discussed. Dr. Nelson emphasizes the importance of normalizing the conversation and encouraging patients to raise the issue with their treatment teams. He walks us through the emotional toll that erectile dysfunction can take on men, noting how it strikes at the core of masculinity and can lead to increased depression, frustration, and a general sense of brokenness. He stresses that it's not just about what happens in the bedroom—erectile issues can spill over into all aspects of a man's life, including his relationship with his partner.Dr. Nelson outlines a range of treatment options, from well-known medications like Viagra to lesser-known but effective methods like penile injections and implants. He breaks down the fear around these options, especially injections, and highlights how pain levels are often far lower than anticipated. Beyond physical treatments, we discuss the emotional and relational work that's often required. One key issue is avoidance—men avoiding sexual situations due to performance anxiety, which can snowball into long-term distance and silence between partners. Dr. Nelson makes it clear: the real risk isn't failure, it's not trying.We also dive into how couples can redefine intimacy. Many men associate sex solely with penetration, while their partners often value closeness and emotional connection more. Dr. Nelson advocates for expanding the sexual repertoire and restoring non-sexual forms of affection, which can be just as meaningful. We talk about the impact of testosterone—how its depletion can lower libido and cause men to unknowingly withdraw from their partners—and how testosterone replacement may be a viable option for some, depending on cancer type and treatment history.As roles shift from caregiver back to partner post-treatment, Dr. Nelson stresses the importance of open communication. He urges couples to work toward understanding each other's perspectives, not convincing each other. He shares an "aha" moment involving a couple who waited five years before seeking help, only to reconnect within three sessions after simply opening the lines of communication. The takeaway: don't wait.We close by pointing listeners toward additional resources, including certified sex therapists and specialized urologists, and Dr. Nelson highlights two key professional directories: SSTAR and AASECT. We're reminded that even the simplest questions—like whether it's okay to kiss your partner—deserve answers. It's on all of us, both patients and providers, to make room for these conversations.More:Episode with Dr. Flores: https://marrowmasters.simplecast.com/episodes/mens-sexual-health-gvhdEpisode with Dr. El Jawahri: https://marrowmasters.simplecast.com/episodes/dr-el-jawahriSSTAR (Society for Sex Therapy and Research) – https://sstarnet.orgAASECT (American Association of Sexuality Educators, Counselors and Therapists) – https://www.aasect.orgThanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:00 - Introduction to Season 19 and Dr. Christian Nelson  01:16 - Normalizing Conversations on Sexual Dysfunction  04:50 - Emotional Toll of Erectile Dysfunction  07:06 - Treatments: Pills, Injections, and Implants  09:03 - Avoidance and Anxiety in Sexual Relationships  12:17 - Expanding the Definition of Intimacy  16:43 - Role of Testosterone in Sexual Health  20:05 - Shifting from Caregiver to Partner  22:17 - Resources and Where to Get Help  26:29 - A Patient Story: Five Years of Silence  28:07 - Closing Thoughts and Resources   National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we talk with caregiver Sylvia Chunn of Nashville, who shares her journey alongside her husband David through his diagnosis of AML, a stem cell transplant, and the ongoing challenges of GVHD. Sylvia walks us through their intense timeline, from David's emergency diagnosis in January 2024 to his transplant in July and their extended stay in Atlanta, away from home and their teenage children, until February 2025. Her husband's transplant was successful in its purpose, but complications like heart failure and GVHD turned their lives upside down.We explore the caregiving experience through Sylvia's eyes, especially navigating chronic GVHD symptoms that affect David's gut, eyes, mouth, joints, and skin. She explains how their lives are now filled with medical appointments, medications, and managing side effects from treatment. Sylvia describes her role as a blend of cheerleader and drill sergeant, ensuring medications are taken and appointments kept, while also offering emotional support.Sylvia emphasizes the importance of self-care during the process. With limited financial flexibility, she found peace in simple things like reading through a Facebook book club, daily personal devotions, and leaning on her faith. Exercise helped at times, although maintaining consistency was difficult. She openly shares that she sought mental health support, including therapy and medication, to deal with stress, guilt, and isolation.The conversation turns to how this journey has affected intimacy and family dynamics. Sylvia candidly reflects on how medical realities changed their physical relationship but ultimately brought them emotionally closer. Time spent together—reading, reminiscing, and watching shows—became a new form of connection. They rediscovered old routines from their early marriage and built a stronger bond through shared trials.Sylvia also shares how their children, especially their youngest teenage twins and their adult daughter in medical school, responded to the crisis. She notes how her kids matured emotionally, became more empathetic, and stepped up in unexpected ways.We close with Sylvia offering heartfelt advice to other caregivers: keep showing up, stay grateful, and never forget the power of hope. She reminds us that while this journey is incredibly difficult, it's also filled with unexpected moments of closeness, resilience, and love.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 - Introduction to Sylvia Chunn01:15 - David's AML Diagnosis and Transplant Decision02:10 - Living Away from Home for Treatment03:40 - Navigating Chronic GVHD05:30 - Caregiver Role and Daily Routine06:40 - Self-Care and Coping Strategies08:20 - Mental Health Support for Caregivers09:40 - Isolation and Infection Risks11:55 - Impact on Intimacy and Marriage16:20 - Parenting Through the Crisis18:40 - Reflections on Family Growth20:40 - Final Thoughts and Advice to Caregivers National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentAbstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapyAbstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infectionsAbstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand diseaseAbstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitorsPresenter:Hanny Al-Samkari, MDThe Peggy S. Blitz Endowed Chair in Hematology/OncologyCo-Director, Hereditary Hemorrhagic Telangiectasia Center of ExcellenceMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AMLAbstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AMLAbstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapyAbstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CMLAbstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKIPresenter:Amir T. Fathi, MDDirector, Leukemia ProgramMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we are joined by Archana Sangha, Senior Medical Science Liaison at Incyte. Archana explains the underlying causes of vitiligo, common misconceptions, and how patients can potentially achieve repigmentation. Archana also discusses how dermatologists can provide compassionate, comprehensive care that acknowledges the experiences of people living with vitiligo, while helping them set realistic treatment expectations. We hope you enjoy!This episode is sponsored by Incyte. Learn more:Website: IncyteLinkedIn: IncyteInstagram: @incyte---DIGA Instagram: @⁠⁠⁠derminterest⁠⁠⁠Today's Host, Marissa Ruppe @marissamarieruppe---For questions, comments, or future episode suggestions, please reach out to us via email at ⁠⁠⁠derminterestpod@gmail.com⁠⁠⁠ ---District Four by Kevin MacLeodLink: **⁠⁠⁠https://incompetech.filmmusic.io/song/3662-district-four**⁠⁠⁠License: **⁠⁠⁠https://filmmusic.io/standard-license**

Welcome to Marrow Masters season 19 with a focus on chronic GVHD. There are so many exciting advances regarding C-G-V-H-D taking place. We'll be talking with a variety of speakers this season, who will share their experiences, advice, coping mechanisms, updates, and tips to make this rare disease more manageable.We will hear from doctors at the forefront of research and treatment, as well as survivors, caregivers, and advocate-leaders in this space.Season 19 of Marrow Masters will be out on December 18, 2025.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this second episode, we discuss how infant microbiomes develop and what factors shape them, and how early life disruptions may increase the risk of disease. The conversation also touches on the hygiene and biodiversity hypothesis, the role of dysbiosis in conditions like atopic dermatitis, and the ongoing challenge of teasing apart whether microbiome shifts are causes or markers of disease.Special thanks to Incyte for supporting this independent medical education program.

The gut and skin microbiomes are an area that is rapidly evolving and holds promise for reshaping our understanding of, prevention, and treatment of pediatric skin disease. This friendly discussion, spanning three episodes, will explore emerging research, theories on microbiome–immune interactions, and what pediatric dermatologists should know about the skin–gut connection.Special thanks to Incyte for supporting this independent medical education program.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über ein Oracle-Beben, eine Tesla-Enttäuschung und eine gekürzte Prognose bei BMW. Außerdem geht es um Seagate, Western Digital, Coreweave, Arista Networks, Vertiv, Dell, Tesla, BMW, Aurubis, Trilogy Metals, Recursion Pharmaceuticals, Absci, Oracle, Pfizer, Biontech, Moderna, AMD, IBM, L&G Pharma Breakthrough UCITS ETF (WKN: A2H9XR), Xtrackers MSCI Genomic Healthcare Innovation (WKN: DBX0R2), Aurubis, IBM, Alnylam, Bristol Myers Squib, Innocare, Incyte und Pharming Group, Lonza, AbbVie, Danaher, Vertex, VanEck Quantum Computing ETF (WKN: A418QM), VanEck Quantum Computing ETF (WKN: A418QM), Rigetti, Quantum Computing, D-Wave, IonQ, WisdomTree Quantum Computing ETF (WKN: A419HV), Alphabet, Honeywell, Microsoft und Deutsche Telekom. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This program, led by Christiaan Scott, MD, Professor of Pediatric Rheumatology at the University of Ottawa and Raphaella Stander, MBCHB, Pediatrician at Atlantic Children's Practice, focused  on three case studies to provide physicians with education on best practices to: 1) suspect and diagnose FOP, 2) monitor and manage younger children with FOP, and 3) monitor and manage older children and adults with FOP. This accredited CME program provides healthcare professional with timely and practical education on fibrodysplasia ossificans progressiva (FOP). It is supported by an educational grant from Ipsen Biopharmaceuticals.To obtain CME credit, visit https://checkrare.com/learning/p-case-studies-in-diagnosing-and-managing-fop/ Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in pediatrics, rheumatology, genetics, family medicine, and orthopedics. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Apply best practices for suspecting and diagnosing FOP.List best practices for managing young children with FOP.Identify best practices to manage older children and adults with FOP.Christiaan Scott, Professor of Medicine, University of OttawaRaphaella Stander, MBCHB, Pediatrician, Atlantic Children's PracticeDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses the following relevant financial relationships with ineligible companies:Grant/Research Support: Regeneron*, Incyte*, Janssen*, Roche*; Speaker's Bureau:  Ipsen*, Regeneron*, Springer*, Jannsen**Relationships have endedDr. Stander has no relevant financial relationships with ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Hidradenitis suppurativa (HS) is, by all accounts, a painful disease.An estimated 3 million Americans live with HS, which is most commonly identified by flare ups as well as painful and unflattering lumps under the skin.Over the past few years, drugmakers have launched campaigns and marketing efforts to bring greater attention and understanding to the disease.Recently, Incyte launched HS Truths – an educational campaign to shine a spotlight on the physical symptoms of the disease as well as the associated mental health challenges.Patient-led, HS Truths provides insights into how frustrating it can be to live with the disease before receiving a proper medical diagnosis – which occurs after an average of seven to 10 years.This week, Managing Editor Jack O'Brien is joined by Stephenie Atkins, senior director, brand lead product strategy and marketing at Incyte, to discuss HS Truths and how it serves to elevate the profile of HS as a disease state.And for our Trends segment, we're talking about all things related to the continued splintering of vaccine policy uniformity in America under Robert F. Kennedy Jr.'s leadership at HHS.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music.

In our final episode focused on the OX40 pathway and its emerging therapies, Dr. Joy Wan moderates a thoughtful discussion with two leaders from the patient advocacy community. Wendy Smith Begolka, MBS, Chief Program and Mission Officer at the National Eczema Association, and Korey Capozza, MPH, Founder and Executive Director of Global Parents for Eczema Research, share their perspectives on incorporating patient priorities into clinical trials and effectively communicating with patients about new and emerging treatments.Disclosures:Joy Wan, MD - Sun Pharmaceuticals – consulting (DMC), Astria Therapeutics – consulting (ad board), Galderma – fellowship funding (paid to Johns Hopkins)Wendy Smith-Begolka, MBS - Amgen/Kyowa, Kirin, Pfizer, Sanofi – advisory board honoraria; Arcutis, Incyte, Galderma – speaker fees; Pfizer, Sanofi – research grants

This week's episode is incredibly close to my heart, and not the usual type of episode I share since this is largely a story about me. Just a few months after becoming a nurse, I was diagnosed with a rare bone marrow disorder known as a myeloproliferative neoplasm (MPN). Since then, I've shared bits of that journey here and there, but today, I'm going deeper with a very special guest: Becca Claassen, an oncology nurse with InCyte and a fellow MPN warrior. Together, Becca and I explore what it's like to live with an MPN and what nurses need to know to better care for patients with this chronic condition. Whether you've never heard of MPNs or you care for oncology patients regularly, this episode offers a powerful blend of clinical insight and personal experience. In this episode, you'll learn: What an MPN (myeloproliferative neoplasm) is and why it's so complex Common types of MPNs and how they affect the body Symptoms patients may experience How to be a more empathetic and informed nurse when caring for someone with a rare chronic illness Our personal stories of diagnosis, treatment, and day-to-day life with an MPN This isn't just a clinical overview. It's a conversation between two nurses who are also patients. I hope it helps you walk away with a better understanding of what your patients might be going through, both physically and emotionally. __________________________ ⁠Voices of MPN Mobile Tracker App⁠ - Share this tool with your MPN patients so they can track their symptoms and have more meaningful conversations with their care team.